Canon Medical to Commence Development of a Rapid Genetic Testing System for Novel Coronavirus (COVID-19)
Reaffirms Company’s Commitment to R&D of Rapid Diagnostic Test Kits
MELVILLE, N.Y. – Canon U.S.A., Inc., a leader in digital imaging solutions, today announced that Canon Medical Systems Corporation (Canon Medical) announced the start of development of a rapid genetic testing system for the novel coronavirus (COVID-19), reaffirming Canon Medical’s commitment to the basic research and development of rapid diagnostic test kits. This project is part of a research program focusing on the development of diagnostic methods for COVID-19 led by the Japan Agency for Medical Research1.
Canon Medical was selected to participate in this research program in cooperation with Nagasaki University. This was in recognition of Canon Medical’s strength in leveraging its technologies in delivering practical solutions to support medical emergencies, notably by supplying Ebola rapid test kits to the Republic of Guinea in 20152, donating Ebola rapid test kits to the Democratic Republic of the Congo in 2019, and through the manufacturing approval and sale of the Genelyzer KIT (a reagent kit for Zika virus RNA testing) in 20183.
The test and the reagents being developed for COVID-19 RNA testing is based on the LAMP method4 developed by Eiken Chemical Co., Ltd., and are to be used with a compact isothermal amplified gene fluorescent detector manufactured by Canon Medical to detect the presence of virus. Compared to the conventional test method of real-time PCR, the LAMP method allows for detection of the virus to be performed more easily and quickly, which makes it suitable for testing in local areas where infection is prevalent.
For more information, please visit www.usa.canon.com.
About Canon U.S.A. Inc.
Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States and to Latin America and the Caribbean markets. With approximately $33 billion in global revenue, its parent company, Canon Inc. (NYSE:CAJ), ranks third overall in U.S. patents granted in 2019† and was named one of Fortune Magazine’s World’s Most Admired Companies in 2020. Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. To keep apprised of the latest news from Canon U.S.A., sign up for the Company’s RSS news feed by visiting www.usa.canon.com/rss and follow us on Twitter @CanonUSA.
† Based on weekly patent counts issued by United States Patent and Trademark Office.
Canon U.S.A., Inc.
1 On the AMED website: www.amed.go.jp/program/list/01/06/covid-19.html
2 Following the outbreak of Ebola hemorrhagic fever in West Africa in 2015, in response to a request from the government of the Republic of Guinea, the Japanese government donated Ebola rapid test kits which were jointly developed by Canon Medical Systems Corporation (formerly Toshiba Medical Systems Corporation) and Nagasaki University.
3 Trade name: Reagents for Zika Virus RNA Testing Genelyzer KIT FGNK-0003A
Approval number: 23000EZX00035000
The company obtained approval for the manufacture and sale of this kit in June 2018 based on joint development work with Nagasaki University in two phases of the project “Establishing surveillance system for the risk of outbreaks of emerging and re-emerging insect-borne diseases in Japan and developing comprehensive insect-borne virus control system” (2016, 2017 onward) (research representative: Masahiro Hayashi, National Institute of Infectious Diseases of Japan) in the Research Program on Emerging and Re- emerging Infectious Diseases.
4 A nucleic acid amplification method known as LAMP (loop-mediated isothermal amplification) developed by Eiken Chemical Co., Ltd.